Abstract

Background and Purpose: Although outcome in intracerebral hemorrhage (ICH) patients is generally not improved by surgical intervention, the use of minimally invasive surgery (MIS) has shown promising results. However, vitamin K antagonist (VKA)-related ICH patients are underrepresented in surgical treatment trials. We therefore assessed the safety and efficacy of a bedside MIS approach including local application of urokinase in VKA-related ICH.Methods: Patients with a VKA-related ICH > 20 ml who received bedside hematoma evacuation treatment (n = 21) at the University Medical Center Freiburg were retrospectively included for analysis and compared to a historical control group (n = 35) selected from an institutional database (University Medical Center Erlangen) according to identical inclusion criteria. Propensity score matching was performed to obtain comparable cohorts. The evolution of hematoma and peri-hemorrhagic edema (PHE) volumes, midline shift, and the occurrence of adverse events were analyzed. Furthermore, we assessed the modified Rankin Scale and NIHSS scores recorded at discharge.Results: Propensity score matching resulted in 16 patients per group with well-balanced characteristics. Median ICH volume at admission was 45.7 (IQR: 24.2–56.7) ml in the control group and 48.4 (IQR: 28.7–59.6) ml in the treatment group (p = 0.327). ICH volume at day 7 was less pronounced in the treatment group [MIS: 23.2 ml (IQR: 15.8–32.3) vs. control: 43.2 ml (IQR: 27.5–52.4); p = 0.013], as was the increase in midline shift up to day 7 [MIS: −3.75 mM (IQR: −4.25 to −2) vs. control: 1 mM (IQR: 0–2); p < 0.001]. No group differences were observed in PHE volume on day 7 [MIS: 42.4 ml (IQR: 25.0–72.3) vs. control: 31.0 ml (IQR: 18.8–53.8); p = 0.274] or mRS at discharge [MIS: 5 (IQR: 4–5) and 5 (IQR: 4–5); p = 0.949]. No hematoma expansion was observed. The catheter had to be replaced in 1 patient (6%).Conclusions: Bedside catheter-based hematoma evacuation followed by local thrombolysis with urokinase appears to be feasible and safe in cases of large VKA-related ICH. Further studies that assess the functional outcome associated with this technique are warranted.Clinical Trial Registration: DRKS00007908 (German Clinical Trial Register; www.drks.de)

Highlights

  • Many attempts have been made at improving the poor functional outcome in intracerebral hemorrhage (ICH) patients

  • One of the major pathophysiological factors related to a poor outcome has been identified as increased hematoma volume, which either causes mechanical disruption or space-occupying mass effects, or can induce the activation of secondary detrimental pathways that lead to peri-hemorrhagic edema, inflammation, and apoptosis [1, 2]

  • In the minimally invasive surgery (MIS) center, 74 patients were identified as vitamin K antagonist (VKA)-related ICH

Read more

Summary

Introduction

Many attempts have been made at improving the poor functional outcome in intracerebral hemorrhage (ICH) patients. Several clinical [3, 4] trials as well as meta-analyses [5, 6] have so far failed to demonstrate a clear clinical benefit of clot removal via craniotomy compared to best medical treatment in ICH patients. Given that very few vitamin K antagonist (VKA)-related ICH patients have been included in the aforementioned clinical trials, the data regarding VKA-associated hemorrhage is even more limited. Outcome in intracerebral hemorrhage (ICH) patients is generally not improved by surgical intervention, the use of minimally invasive surgery (MIS) has shown promising results. Vitamin K antagonist (VKA)-related ICH patients are underrepresented in surgical treatment trials.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call